Navigation Links
N30 Pharma Announces Financing and Addition to Board
Date:5/11/2010

BOULDER, Colo., May 11 /PRNewswire/ -- N30 Pharma (N30), a biopharmaceutical company focused on the discovery and development of a new class of proprietary therapeutics that conserve endogenous, bioactive nitric oxide, announced today that it has completed a $10 million financing and expanded its Board of Directors.

Joining the Company's Board of Directors will be Dr. Howard Furst of Deerfield Management.

"I am pleased with this successful financing. It will provide resources to move our first drug, N6022 into human testing, as well as support the development of other novel new drugs from our discovery and development platform. In addition, Dr. Furst brings a wealth of healthcare investment and medical expertise to our Board," commented Charles Scoggin MD, CEO of N30.

About N30 Pharma N30 Pharma is a clinical-stage company developing s-nitrosothiol (SNO)-based therapies for major unmet needs in respiratory, cardiovascular, and inflammatory diseases. N30 drugs target s-nitrosoglutathione reductase (GSNOR), the only druggable enzyme that consumes s-nitrosoglutathione (GSNO), a central regulator of the endogenous nitric oxide pool. GSNO, and other SNO's are important modulators of inflammation as well as airway and vascular smooth muscle. N30 is a privately held company headquartered in Boulder, Colorado.


'/>"/>
SOURCE N30 Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... MN and Bethesda, MD (PRWEB) , ... April ... ... Advancing Innovation announce the formation of a unique intellectual property (IP) sharing and ... potential of their most promising inventions. A main component of this effort is ...
(Date:4/19/2017)... ... April 18, 2017 , ... A number of new ... webinar, which is part of the Protein and Cell Analysis Education Webinar Series ... where this technology fits in current and future applications. , Many flow cytometers ...
(Date:4/19/2017)... NY (PRWEB) , ... April 19, 2017 , ... ... combat Clostridium difficile (C. diff) infections through education and advocacy. Founded in ... life to a C. diff infection, the foundation has become the most-consulted source ...
(Date:4/19/2017)... 19, 2017 Veracyte, Inc. ... it will report its first quarter 2017 financial ... 2017. Following the announcement, Veracyte,s management will host a live ... discuss the company,s financial results and business progress. ... may be accessed by visiting Veracyte,s website at  http://investor.veracyte.com . ...
Breaking Biology Technology:
(Date:3/28/2017)... , March 28, 2017 ... Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video ... and Region - Global Forecast to 2022", published by ... in 2016 and is projected to reach USD 75.64 ... 2017 and 2022. The base year considered for the ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... , March 23, 2017 The report "Gesture Recognition and ... Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, the market ... CAGR of 29.63% between 2017 and 2022. Continue ... ... ...
Breaking Biology News(10 mins):